Avoid aggressive deficits
the honest gap is that CJC/ipa has almost no controlled human data either way
We're committed to not just providing the highest quality peptides today, but also to supporting the breakthroughs of tomorrow
Important precautions include: GLP-1 receptor agonists should not be used in patients with type 1 diabetes or diabetic ketoacidosis Caution is advised in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 These medications are not recommended in severe gastrointestinal disease They should not be used during pregnancy or breastfeeding, and semaglutide should be discontinued at least 2 months before a planned pregnancy [1] [7] Your GP or specialist will assess your individual circumstances to determine suitability
Customized health programs for weight management, anti-aging, and hormone optimization
A randomized, double-blind, placebo-controlled phase 2 study comparing the efficacy and safety of tirzepatide versus placebo in 196 patients with nonalcoholic steatohepatitis (SYNERGY-NASH) with or without diabetes is currently underway and is estimated to complete in 2024
